<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03408665</url>
  </required_header>
  <id_info>
    <org_study_id>STEREOLIVER-1704</org_study_id>
    <nct_id>NCT03408665</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer</brief_title>
  <acronym>STEREOLIVER</acronym>
  <official_title>Phase II Study, Stratified, Non-randomized, Estimating SBRT Efficiency and Toxicity in Primary and Secondary Liver Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intervention research involving the human person, phase II, prospective, multicentric,
      non-randomized and multi-cohort study. The eligibility criteria are broad, on purpose, so
      every patient, able to be treated by SBRT and unable to participate in another trial (non
      eligible patient or non included centers), can be included in this national study, in a
      prospective way.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will first go through an inclusion check-up consisting of:

        -  a clinical exam: disease history, previous treatments, weight, height, patient's
           performance status (ECOG) and HCC status.

        -  a biological test: biochemical (total bilirubin, ASAT-ALAT, LDH, albumin, alkaline
           phosphatases, GGT), hematological (if the patient is going to receive a fiducial),
           alphafoetoprotein (for HCC) and pregnancy test (if applicable)

        -  a tumor assessment: using a CT-scan or a MRI and using RECIST or mRECIST (if HCC), plus
           other morphological exams if judged useful by the investigator This check-up has to be
           realized within 28 days before inclusion. Then, the use of fiducial is optional.

      Before the beginning of the treatment, a pre-therapeutic check-up is done:

        -  the inclusion check-up has to be done a second time if the treatment begins more than 28
           days after the first one

        -  Tracking scanner.

      The SBRT treatment is done in 3 to 6 times and no specific SBRT techniques are asked for, the
      investigator can choose according to the center habits.

      After the treatment, a follow-up will be realized at 3, 6, 9, 12, 18, 24, 30 and 36 months
      and then once a year until the last patient included reach their 36th month of follow-up. The
      follow-up check-up consists of a clinical exam, biological test, tumor assessment and
      tolerance assessment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the SBRT efficiency in term of local progression-free survival (L-PFS) for patient who are to be treated with SBRT in one of the 3 following situations : inoperable hepatocellular carcinoma, liver metastasis and nodular cholangiocarcinoma.</measure>
    <time_frame>From baseline to 36 months following up.</time_frame>
    <description>Local progression-free survival (L-PFS) thanks to Kaplan-Meier method from registration date to date of local progressive disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate the SBRT efficiency in a prospective way, in term of local progression-free survival (L-PFS) for patient treated with SBRT in the 3 considered clinical situations.</measure>
    <time_frame>From baseline to 36 months following up.</time_frame>
    <description>Local progression-free survival (L-PFS) thanks to Kaplan-Meier method from registration date to date of local progressive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the different SBRT techniques used in the study for liver tumor.</measure>
    <time_frame>From baseline to 36 months following up.</time_frame>
    <description>Description of SBRT techniques used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the SBRT feasibility by comparison of planned SBRT to performed SBRT.</measure>
    <time_frame>From baseline to 36 months following up.</time_frame>
    <description>Description of reasons leading to SBRT scheme modification or interruption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the SBRT efficiency in a prospective way, in term of overall survival (OS) for patient treated with SBRT in the 3 considered clinical situations.</measure>
    <time_frame>From baseline to 36 months following up.</time_frame>
    <description>Overall survivall thanks to Kaplan-meier method, from registration date to date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the SBRT efficiency in a prospective way, in term of progression-free survival (PFS) for patient treated with SBRT in the 3 considered clinical situations.</measure>
    <time_frame>From baseline to 36 months following up.</time_frame>
    <description>Progression-free survival (PFS) thanks to Kaplan-Meier method from registration date to date of progressive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the immediate and delayed toxicity.</measure>
    <time_frame>From baseline to 36 months following up.</time_frame>
    <description>Description of toxicity associated to SBRT or the fiducial use thanks to NCI-CTCAE v4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the quality-adjusted survival (Q-TWiST) for patients in each of the 3 considered clinical situations.</measure>
    <time_frame>From baseline to 36 months following up.</time_frame>
    <description>Q-TWIST consists in 3 clinical states: time in toxicity before progressive disease, time in progressive disease, time without toxicity nor progressive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the proportion of patients for whom an hospitalization is required.</measure>
    <time_frame>From baseline to 36 months following up.</time_frame>
    <description>during the treatment and until 3 months after and the cumulative duration of the hospitalization over those 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the impact of the different SBRT techniques on SBRT efficacy according to L-PFS.</measure>
    <time_frame>From baseline to 36 months following up.</time_frame>
    <description>Estimation of impact of SBRT technique used on SBRT efficacy according to L-PFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the impact of the different SBRT techniques on SBRT efficacy according to PFS.</measure>
    <time_frame>From baseline to 36 months following up.</time_frame>
    <description>Estimation of impact of SBRT technique used on SBRT efficacy according to PFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the impact of the different SBRT techniques on SBRT efficacy according to OS.</measure>
    <time_frame>From baseline to 36 months following up.</time_frame>
    <description>Estimation of impact of SBRT technique used on SBRT efficacy according to OS.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotaxic Body Radiation Therapy administred in 3 to 6 fractions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>3 sessions at least, up to 6. Neither specifc device is imposed.</description>
    <arm_group_label>SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  If fiducial use, proper hematological functions (for fiducial placement) : PT &gt; 50% ;
             platelets &gt; 50,000/L ; aPTT &lt; twice the normal value

          -  With primary or secondary liver tumor and matching one of the following situations:

          -  Liver Metastasis (LM): anatomopathologic diagnosis of the primary tumor

          -  Hepatocellular Carcinoma (HCC): diagnosis achieved through biopsy or through
             non-invasive methods approved by AASLD criteria (Bruix, 2011)

          -  Cholangiocarcinoma (CC): diagnosis achieved through biopsy

          -  Meet the requirements for SBRT treatment:

          -  Liver Metastasis (LM): oligometastatic disease

          -  Hepatocellular Carcinoma (HCC): non eligible lesion to curative surgery

          -  Cholangiocarcinoma (CC): nodular lesion

          -  Able to receive a SBRT treatment according to the multidisciplinary consultation
             meeting

          -  Tumor evaluated by CT-scan or MRI in the 28 days prior to inclusion

          -  Affiliation to the National Social Security System

          -  With informed and signed consent

        Exclusion Criteria:

          -  Eligibility to a curative surgery according to the multidisciplinary consultation
             meeting

          -  Contraindication to SBRT (especially Cirrhose Child C)

          -  Pregnant or breastfeeding women

          -  Patient Under guardianship or tutorship

          -  Impossibility to submit at the study procedures due to geographic, social or mental
             reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier MIRABEL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien THERY</last_name>
    <phone>+33320295918</phone>
    <email>promotion@o-lambret.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier MIRABEL, MD</last_name>
      <phone>+33320295911</phone>
      <email>x-mirabel@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier MIRABEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léonard de Vinci</name>
      <address>
        <city>Dechy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franck DARLOY, MD</last_name>
      <phone>+33327086062</phone>
      <email>fdarloy@clinique-psv.fr</email>
    </contact>
    <investigator>
      <last_name>Franck DARLOY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damien CARLIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis GRAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lise UCLA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Régional du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier RIOU, MD</last_name>
      <phone>+33467614737</phone>
      <email>olivier.riou@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier RIOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David AZRIA, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen BENEZERY, MD</last_name>
      <phone>+33492031269</phone>
      <email>karine.benezery@nice.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Karen BENEZERY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérôme DOYEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorraine KREBS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas MAGNE, PhD</last_name>
      <phone>+33477917434</phone>
      <email>nicolas.magné@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas MAGNE, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grégoire PIGNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amel REHALIA-BLANCHARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georges NOEL, PhD</last_name>
      <phone>+33388252485</phone>
      <email>gnoel@strasbourg.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Georges NOEL, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Baptiste CLAVIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrey KELLER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine SCHUMACHER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Tours - Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilles CALAIS, PhD</last_name>
      <phone>+33247478265</phone>
      <email>gilles.calais@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles CALAIS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie CHAPET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume JANORAY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier PEIFFERT, PhD</last_name>
      <phone>+33383598431</phone>
      <email>d.peiffert@nancy.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Didier PEIFFERT, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Sophie BAUMANN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie RENARD-OLDRINI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Agathe SERRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2018</study_first_submitted>
  <study_first_submitted_qc>January 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

